Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Crinetics Pharmaceuticals, Inc. reported revenue of $8M, up 640.7% year over year. Operating margin was -6714.8% and net margin -6046.2%, on a free-cash-flow margin of -4985.5% with capital expenditure at 74.9% of revenue. Every figure is computed directly from CRNX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $8M | -6714.8% | -6046.2% |
| FY2024 | $1M | -32613.5% | -28720.7% |
| FY2023 | $4M | -5547.2% | -5345.9% |
| FY2022 | $5M | -3544.1% | -3460.4% |
| FY2021 | $1M | -9990.9% | -9985.3% |
How does CRNX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.